tikr.com
Cure8 news brief
Why This Matters
New Phase 2a data suggest a two‑drug combo from AbbVie may produce higher endoscopic remission than Skyrizi alone, which could matter for future treatment options and for patients who have failed prior advanced therapies. For patients, this is early-phase news and not an immediate treatment change.
Who Should Pay Attention
Patients with Crohn’s disease (especially those who've failed other biologics), clinicians who treat IBD, researchers tracking combination biologic strategies, and investors following AbbVie’s drug pipeline.
Study Snapshot
Story typeBusiness news
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
AbbVie’s ABBV-466 combo showed higher endoscopic remission at Week 24 than Skyrizi alone in the Phase 2a release, but the study was open-label, ongoing, and the company did not report p-values in the announcement. The Week 12 primary endpoint difference was smaller.
The company will pursue additional dose-finding (Phase 2b) and aims for a co-formulated subcutaneous product in future trials. The article frames the results in the context of AbbVie’s commercial outlook and stock valuation; it is not a peer-reviewed study publication and does not provide full trial data or detailed safety analyses.
Keep In Mind
The article is a business/stock analysis citing company-released Phase 2a data presented at a meeting. The trial was open-label, ongoing, and lacked reported p-values in the release; full peer-reviewed trial data are not included. The company projects years before any commercial product, and additional trials (Phase 2b) are planned.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationtikr.com
Indexed viaGoogle News
Source typeWeb article
PublishedOct 20, 2026, 8:47 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
As AbbVie's Crohn's combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
This mid-stage trial suggests a dual-targeting combo may improve endoscopic remission rates in Crohn’s disease compared with IL-23 inhibition alone, which could influence future treatment options and company strategies...
AbbVie's dual therapy tops monotherapy arms in Phase IIa Crohn's endoscopic remission
A new dual-targeting combination (IL-23 + α4β7) showed higher endoscopic remission rates than either drug alone in a Phase IIa Crohn's study, suggesting a potential new approach for patients who need better mucosal...
AbbVie ABBV-466 Achieves 40.5% Crohn's Remission | Grafa
New Phase 2a data suggest a combination therapy (ABBV-466) produced higher endoscopic remission at Week 24 than either component alone — a potential sign that multi-target approaches might improve Crohn's outcomes.